- AdventHealth
Accurately determining food intake remains a challenge in nutrition research. A new study published in Nature Metabolism, co-authored by AdventHealth Translational Research Institute (TRI) investigator Karen D. Corbin, PhD, RD, introduces a metagenomics-powered approach to accurately track dietary intake from gut microbiome samples.
Developed by Christian Diener, PhD, in the Gibbons Lab at the Institute for Systems Biology (ISB), the new method, called MEDI (Metagenomic Estimation of Dietary Intake), detects food-derived DNA in stool samples to estimate dietary intake, allowing for data-driven diet tracking without the use of questionnaires. Data from AdventHealth TRI’s Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance study (NCT02939703) published in Nature Communications in 2023 helped to validate this new method.
MEDI leverages stool metagenomics, a sequencing of all the DNA present in fecal samples, including microbial, human, and food-derived DNA. This non-invasive, data-driven approach offers an objective alternative to traditional food diaries and questionnaires, which are still the gold standard in dietary assessment but can suffer from misreporting and compliance issues.
Key findings of the latest study include the following:
- An Alternative to Questionnaire-Based Diet Tracking: Leveraging a database of more than 400 food items and over 300 billion base pairs of genomic information, MEDI accurately detected food intake patterns in infants and adults, and across two controlled feeding studies.
- Connecting Dietary Intake to Nutrition: MEDI converts the relative abundance profile of specific food items into nutrient profiles, assuming a 100-gram portion. These nutrient profiles show good agreement with data from controlled feeding studies, including AdventHealth’s microbiome study.
- Identified Diet-Related Health Risks: Without food logs, MEDI pinpointed dietary features linked to metabolic syndrome in a large clinical cohort.
“This is the perfect example of how collaboration advances science,” shares Dr. Corbin. “The data from our original TRI study was a small but important piece of this new research. We’re excited about the potential power this work holds to expand our overall understanding of interactions between diet and the gut microbiome and to further development of precision nutrition approaches that could help reduce obesity and other chronic diseases.”
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Participating in Phase I Clinical Trial of Potential New Oral Immunotherapy Treatment for Mild to Moderate Ulcerative Colitis
AdventHealth Research Institute is the first in Central Florida to participate in the expansion phase of a clinical trial exploring a potential new oral immunotherapy treatment for mild to moderate...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...